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Introduction
The rational use of medicines remains one of the most 
important directions of public health, especially in socio-
medical diseases, including arterial hypertension (AHT). 
Hypertensive disorders complicate 5-10% of the pregnant 
and still now remain a leading cause of maternal mortality. 
The medicine data based on available and currently known 
evidences in the field of clinical pharmacology allow deter-
mination of the principles of selection and assessment of the 
use of medicines in the above-named diseases, which allow 
not only the optimization of rational use but also the reduc-
tion of the necessary expenditures and the increase of the 
harmlessness of the treatment [3, 4, 16, 19].
 The aim of the study was to perform a pharmaco-thera-
peutic analysis compared with the elucidation of the groups 
of drugs and antihypertensive medicines used in the treat-
ment of patients with hypertension and treatment of hyper-
tension during pregnancy [2,3,4,5,8,10,18].
Material and methods
A survey study was conducted out by physicians from 
the medical institutions of Chisinau municipality in order 
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Abstract
Background: The rational use of medicines remains one of the most important directions of public health, especially in socio-medical diseases, including 
arterial hypertension. 
Material and methods: The study involved 28 cardiologists and 84 internists who, based on a set of questionnaires, expressed their opinion on ambulatory 
treatment of patients with arterial hypertension. Also 21 internists, 6 cardiologists and 6 obstetrician-gynecologists expressed their opinion on treatment 
of pregnancy-induced hypertension.
Results: Cardiologists and internists recommended angiotensin-converting-enzyme inhibitors (ACE inhibitors) in 28% of cases, diuretics – in 23% of 
cases, beta-blockers (BB) – in 20, 4% of cases, calcium channel blockers (CCB) – in 13.7% of cases, angiotensin receptor blockers (ARB) – in 13.6% of 
cases for ambulatory treatment of patients with arterial hypertension. The antihypertensive drugs from other pharmacological groups (with central action, 
alpha-blockers, arteriodilators, sympatholytics, etc.) were prescribed in only 1.3% of patients. On treatment of hypertension in pregnancy showed that all 
physicians – 100% recommended as first-line agent for treatment of hypertension during pregnancy centrally acting antihypertensive drug Methyldopa. 
For second-line treatment they recommended CCB – in 36.36% of cases, alpha-adrenoblockers – in 24.24% of cases, BB – in 21.21% of cases, diuretics – in 
12.12% of cases and 3% for ACE inhibitors and ARB. For treatment pre-eclampsia and eclampsia seizures in 84.85% of cases is recommended Magnesium 
sulfate and 15.15% mention labetalol, hydralazine and sodium nitroprusside. 
Conclusions: ACE inhibitors, diuretics, BAB, CCB and ARB have been first-line drugs in the arterial hypertension (AHT) treatment.  For treatment 
of pregnancy-induced hypertension physicians recommended centrally acting antihypertensive drug Methyldopa. For second-line treatment they 
recommended calcium channel blockers (CCB), alpha-adrenoblockers, beta-blockers (BB) and diuretics. As third-choice in treatment of severe 
hypertension in preeclampsia are selected direct vasodilators as hydralazine, labetalol, sodium nitroprusside, and the most widely used in preeclampsia 
and eclampsia remains magnesium sulfate.
Key words: arterial hypertension, antihypertensive drugs, angiotensin-converting-enzyme inhibitors
to assess the incidence of prescribing different groups of 
antihypertensive drugs in the period October, 2015 – No-
vember, 2017. The study involved 28 cardiologists and 84 
internists who, based on a set of questionnaires, expressed 
their opinion on ambulatory treatment of patients with ar-
terial hypertension to determine the following aspects: fre-
quency of use of the main groups of antihypertensive drugs 
and their representatives in patients with hypertension; cor-
respondence of the pharmacotherapy stage and the degree 
of hypertension; the share of fixed combinations drugs for 
complex pharmacotherapy of arterial hypertension.  Also 21 
internists, 6 cardiologists and 6 obstetrician-gynecologists 
expressed their opinion on treatment of pregnancy-induced 
hypertension to determine the frequency of use of main 
groups of antihypertensive drugs.
Results
The results of the carried out study showed that cardi-
ologists and internists recommended angiotensin-convert-
ing-enzyme inhibitors (ACE inhibitors) in 28% of cases, di-
uretics – in 23% of cases, beta-blockers (BB) – in 20.4% of 
cases, calcium channel blockers (CCB) – in 13.7% of cases, 
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angiotensin receptor blockers (ARB) – in 13.6% of cases 
for ambulatory treatment of patients with hypertension. 
The hypotensive drugs from other pharmacological groups 
(with central action, alpha-blockers, arteriodilator, sym-
patholytics, etc.) were prescribed in only 1.3% of patients. 
The reported data are in accordance with the national and 
international guidelines recommendations and reflect the 
contemporary strategy of approaching the hypertensive pa-
tient in terms of the initial and final goal of antihypertensive 
therapy [2, 3, 4, 5]. The analysis of literature data reveals that 
ACE inhibitors, ARB, BAB, CCB and diuretics are consid-
ered first-line antihypertensive drugs in the AHT treatment, 
and alpha-adrenoblocks, central-acting drugs, vasodilators 
and renin inhibitors are part of second-line antihyperten-
sive medicines [3, 4, 15, 28, 31, 33].
The analysis of the drugs prescription from each phar-
macological group was relevant to the fact that doctors rec-
ommended a wide range of representatives, selection being 
based on the particularities of drug release (free or com-
pensated), age aspects, associated diseases, and target organ 
damage. Among the ACE inhibitors, doctors mentioned in 
the questionnaires almost all medicines registered in the 
Republic of Moldova.
Thus, the most frequent drugs in this group were ramipril 
(28.9%) and lisinopril (28.5%), followed by captopril (18.9%), 
enalapril (18.2%) and perindopril (4.9%). The angiotensin-
converting-enzyme inhibitors, as first-line drugs in the AHT 
treatment, have an overwhelming evidence base in numer-
ous trials and clinical guidelines, including patients with as-
sociated diseases such as diabetes mellitus, ischemic heart 
disease, cardiac failure, cardiac arrhythmias, atherosclerosis, 
renal diseases [2, 3, 4, 6, 15, 22, 26].
The ACE inhibitors pharmacodynamic profile is quite 
varied in terms of blood levels changes of angiotensin-
converting-enzyme, angiotensin I, angiotensin II, renin, 
aldosterone and haemodynamic parameters, and also by or-
ganoprotective properties. The mechanism of action partic-
ularities determine the decrease of angiotensin II levels by 
blocking the respective more significant enzyme in organs 
and tissues than in plasma, especially in long-term treat-
ment. Concurrently, ACE inhibitors also inhibit kinase II by 
increasing bradykinin content by stimulating the release of 
nitrogen monoxide and vasodilator prostaglandins. 
The hypotensive action of ACE inhibitors is also due to 
other mechanisms: sympathetic tone activity reduction (de-
crease in adrenaline and noradrenaline level); aldosterone 
secretion decrease (natriuretic effect); endothelin secretion 
suppression; endothelial dysfunction amelioration.
Hemodynamic (reduction of peripheral vascular re-
sistance, post- and preload, increased renal flow, etc.) and 
cardiac effects (regression of left ventricular hypertrophy, 
increase of coronary flow, reduction of postinfarction mor-
tality, improvement of cardiac insufficiency, decrease of 
nitrate tolerance) are responsible for diminishing the myo-
cardial remodeling progression and vascular smooth mus-
cle hypertrophy to prevent damage to organs and systems 
which reflect beneficially  on the quality of life, morbidity 
and mortality of patients with cardiovascular diseases [3, 4, 
6, 15, 16, 24, 26, 28].
Diuretics, as expected, occupied the second position in 
doctors’ preferences. Indapamide (35.7%), spironolactone 
(26.8%), furosemide (16.5%), torasemide (12.7%) and hy-
drochlorothiazide (8.3%) were among the diuretics recom-
mended to the patients. The use of diuretics in the HTA 
treatment is determined by the drugs ability to reduce blood 
pressure and to remove refractory mechanisms in other hy-
potensive groups. The antihypertensive action of diuretics 
is determined by various mechanisms depending on the 
duration of use. Thus, blood pressure lowering is achieved 
by the moderate effect of natriuresis with the reduction of 
circulating blood volume and preload, respectively, at the 
initiation of treatment (the first 4-6 weeks). The circulating 
blood volume is restored in long-term use and blood pres-
sure lowering is possibly achieved by reducing vascular tone 
through several mechanisms: synthesis of vasodilator pros-
taglandins (indapamide, furosemide, torasemide); blockage 
of calcium channels (indapamide); activation of potassium 
channels (indapamide); reducing vascular intimal infiltra-
tion with sodium ions [3, 4, 20, 31, 33].
The quite frequent use of indapamide, a third genera-
tion non-thiazide diuretic, is argued by pharmacodynamic 
peculiarities, good tolerability and harmlessness, a salu-
tary preparation in the long-term treatment of AHT. Inda-
pamide, in addition to the hypotensive effect particularities, 
is characterized by beneficial influences on thiazides, on 
glucose metabolism (it does not produce hyperglycemia, 
does not disturb the sensitivity of peripheral tissues to in-
sulin), lipid (a minimal effect on cholesterol level, triglyc-
erides, increases the content of high density lipoproteins), 
electrolytic (practically does not produce hypokalaemia) 
and purine (does not increase uric acid level) [20, 31, 33].
The elucidation of new pathogenetic aspects of AHT, 
including refractoriness in the first-line drugs, has demon-
strated the role of aldosterone in cardiovascular pathology 
through genomic and non-genomic mechanisms. Thus, the 
“aldosterone rickets” phenomenon was described, which 
occurs in AHT patients treated with inhibitors of the renin-
angiotensin-aldosterone system due to incomplete inhi-
bition of mineralocorticoid activity. The use of antagonist 
competitors of aldosterone (spironolactone, eplerenone), 
considered to be the second, third or even the forth-line 
drugs, under these conditions, contributed to the increase 
of efficacy and removing refractoriness in antihypertensive 
drugs [27, 30].
Spironolactone, a non-competitive antagonist of aldo-
sterone, contributed to prevent progression of target organ 
damage and the development of complications, loss of po-
tassium and magnesium ions. However, the high adverse re-
actions incidence (breast tightening, gynecomastia, erectile 
dysfunction, amenorrhea, hirsutism, etc.), determined by 
the steroid structure and influence on androgen receptors, 
limits patients’ compliance with the treatment.
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In this context, a particular interest is given to eplere-
none, a selective antagonist of aldosterone, a product that 
is characterized by better tolerability and harmlessness. At 
the same time, it is estimated that, if spironolactone pre-
dominantly influences the mineralocorticoid genomic 
mechanisms, eplerenone is able to annihilate non-genomic 
ones, thus exhibiting a faster effect [1, 20, 27, 30, 31, 33].
The lower incidence of loop diuretics use is explicable 
because these drugs are prescribed by doctors in emer-
gency situations, in severe AHT and associated with com-
plications; in case of the renal function alteration (2nd-3rd 
degree). The rather high frequency of torasemide prescrip-
tion due to its advantages over furosemide (effect up to 24 
hours, less incidence of side effects, including the severe 
ones, better treatment compliance in patients) is significant 
[20, 31, 33].
Hydrochlorothiazide, although had the lowest use in-
cidence, remains a thiazide in demand, especially in the 
forms combined with ACE inhibitors, ARB, BB, CCB, due 
to the moderate and constant antihypertensive effect, the 
ability to decrease the counterregulatory mechanisms in 
the case of refractoriness to other hypotensives, despite 
characteristic metabolic reactions [17, 20, 31, 33].
Beta-blockers were recommended relatively quite fre-
quently (20.4%), which corresponds to the literature data 
[7, 8, 11, 19, 24].  Bisoprolol (45.7%), followed by metopro-
lol (29.2%), nebivolol (8.1%), and atenolol (7.7%) were most 
frequently prescribed drugs from this group. Carvedilol 
and propranolol were recommended with lower incidence. 
The relatively high incidence of BB in hypertensive patients 
is determined by an increase in the number of drugs of this 
group, especially cardioselective ones (bisoprolol, atenolol, 
metoprolol, acebutolol, etc.) and with vasodilatory action 
(nebivolol, carvedilol). The antihypertensive effect of BB 
is determined by several mechanisms: heart rate decrease; 
decrease of renin secretion and renin-angiotensin-aldoste-
rone system activity; modification of the aorta barorecep-
tors sensitivity and sino-carotid glomerus; reduction of 
sympathetic central genesis; dilation of vessels by nitrogen 
monoxide production, alpha-adrenoreceptors blockade or 
direct myotropic action [3, 4, 7, 8, 29].
Among the CCB, the largest share goes to the dihydro-
pyridine derivatives (73.1%), followed by the benzothiaze-
pine derivatives (13.4%) and phenylalkylamine derivatives 
(10.7%). Dihydropyridines were represented by amlodip-
ine (61.8%) and nifidipine (11.3%), and by lercanidipine, 
lacidipine, etc. in a smaller percentage.
Among the CCB with concomitant action on vessels 
and heart, diltiazem was prescribed in 13.4% of cases and 
verapamil in 10.7% of cases. The more frequent use of am-
lodipine is argued by pharmacological peculiarities: high 
bioavailability due to lipophilic properties; rapid onset of 
action; absence of neuroendocrine and sympathetic reflex 
mechanisms on heart and metabolism; the long half-life 
that determines convenience in administration (once a 
day) and patient’s good compliance with the treatment; a 
lower incidence of side effects; increase in nitrogen monox-
ide production; the antioxidant properties presence.
These priorities determine the use of amlodipine as a 
first-line antihypertensive drug as a monotherapy and an 
important component in combined therapy with almost all 
hypotensive groups including patients with comorbidities 
(angina pectoris, atherosclerosis, diabetes mellitus, kidney 
disease) [3, 4, 11, 14, 23].
On the basis of randomized studies and meta-analysis, 
it was determined that CCB does not cede to ARB, ACE in-
hibitors, BAB, diuretics and alpha-adrenoblockers in blood 
pressure control, risk of cardiovascular (death, myocardial 
infarction, heart failure) and cerebrovascular events [14, 24].
Doctors recommended ARB with a similar incidence 
of CCB – 13,6%. Losartan (61.8%) and valsartan (33.2%) 
predominate among the drugs of this group. It is neces-
sary to mention that in the doctors’ preferences there were 
also mentioned such ARB as irbesartan (2.5%), telmisartan 
(1.25%), and candesartan (1.25%), drugs with some more 
advantageous pharmacological features welcomed in cer-
tain clinical situations. Angiotensin receptor blockers in 
European countries are prescribed to 20-25% of AHT pa-
tients because they are considered as the basic pathogenetic 
therapy that allows safe and adequate blood pressure con-
trol, prevention of target organ damage and complications. 
The use of ARB provides for a more complete blockade of 
the renin-angiotensin-aldosterone system because it blocks 
the action of angiotensin II on specific (type 1) receptors 
produced not only by angiotensin converting enzyme but 
also by alternative routes (chymase, etc.). At the same time, 
angiotensin II activity is maintained on 2nd type of angio-
tensin receptors while maintaining physiological effects 
(vasodilation, antiproliferative action, etc.). Concomitantly, 
metabolism of bradykinin, encephalins and other biologi-
cally active peptides, responsible for some specific side ef-
fects of ACE inhibitors that activate the quinine system, is 
not affected. The drugs of this group are characterized by 
a stable antihypertensive effect over 24 hours with a stable 
clinical effect after 3-4 weeks. Sartans exhibit favorable 
metabolic actions on lipid and carbohydrate metabolism, 
beneficial effects in patients with diabetes mellitus, dyslip-
idemias, metabolic syndrome, atherosclerosis of vessels. 
Clinical studies have shown decrease of glucose and insulin 
resistance level (stimulation of PPAR- nuclear receptors in 
adipose and muscle tissue, hepatocytes). It was proved the 
ARB capacity to reduce the contents of triglyceride and low 
density lipoprotein cholesterol. These effects, along with the 
improvement of endothelial dysfunction, will be welcomed 
in patients with the mentioned pathologies [3, 4, 6, 16, 22, 
25, 26, 32].
Among the hypotensive preparations in other groups, 
the doctors have opted for centrally acting anti-hyperten-
sives and alpha-1-adrenoblocking agents. It is necessary to 
mention that the imidazoline receptor agonist, moxonidine 
(52.5%), predominates among the medically active drugs 
compared to the methyldopa (20%) and clonidine (17.5%) 
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alpha-2 adrenomimetics. Among the selective alpha-ad-
renergic blockers, doxazosin was recommended in 10% of 
cases.
The therapeutic behaviour according to the degree of 
arterial hypertension was another aspect of the pharmaco-
epidemiological study. Thus, the investigations analysis re-
vealed that doctors preferred monotherapy (86.4%), and the 
association of 2 drugs in 12.8% and association of 3 drugs 
only in 0.8%, in case of hypertension of the first degree.
In patients with arterial hypertension of second degree, 
the doctors mentioned the need for prescribing 2 drugs 
(65.5%), while monotherapy was sufficient in 21.2%, and 
triple therapy was required in 13.3% of patients. For hy-
pertension of third degree, treatment with 3 hypotensive 
drugs (46.6%) is recommended. At the same time, doc-
tors mentioned that about 38.7% of the patients responded 
adequately to treatment with 2 antihypertensives, and even 
4 hypotensive preparations were recommended in 14.7% of 
patients. These data fully reveal the actual clinical situation 
due to target organ damage with the progression of high 
blood pressure.
The survey showed that doctors preferred associations 
between one drug from different groups (64.4%) in case of 
combined antihypertensive drug therapy, while fixed-dose 
combinations were recommended in only 26.7% of cases. 
The association of one drug with fixed-dose drugs combina-
tions was used in 8.9% of cases.
The results on treatment of hypertension in pregnancy 
showed that all physicians -100% (21 internists, 6 cardiolo-
gists and 6 obstetrician-gynecologists) recommended as 
first-line agent for treatment of pregnancy-induced hyper-
tension, centrally acting antihypertensive drug methyldopa. 
Accordingly to literature data methyldopa is one of the most 
widely used drugs for the treatment of hypertension dur-
ing pregnancy (Category B, safe, accordingly to Food and 
Drugs Administration, FDA, USA classification of drugs 
in pregnancy). It is a prodrug metabolized to alpha meth-
ylnorepinephrine, which then replaces norepinephrine in 
the neurosecretory vesicles of adrenergic nerve terminals. 
Methyldopa inhibits vasoconstriction via a central mecha-
nism by reducing catecholamine release [3, 4, 18]. It de-
creases central sympathetic outflow, decreasing systemic 
vascular resistance, without decreasing cardiac output BP 
control is gradual, over six to eight hours, because of the 
indirect mechanism of action. Treatment with methyldopa 
has been reported to prevent subsequent progression to se-
vere hypertension in pregnancy and does not seem to have 
adverse effects on utero-placental or fetal hemodynamics. 
Adverse effects are based on pharmacodynamics effects – 
central alpha-2 blocking effect or decreased peripheral sym-
pathetic tone. This drug can cause decreased mental alert-
ness and impaired sleep, leading to sense of fatigue in some 
or depression in others. Still other observed side effects are 
decreased salivation, leading to xerostomia (chronic dry 
mouth), elevated liver enzymes in 5%; hepatitis and hepatic 
necrosis have been reported. Some patients will develop a 
positive antinuclear antigen or antiglobulin (Coombs’) test 
with chronic use, which may occasionally cause clinical he-
molytic anemia. However, it is not considered to be tera-
togenic based on limited clinical study data and forty-year 
clinical experience [3, 4, 8, 18]. Another central acting agent 
is clonidine (Category C, less safe, accordingly to FDA clas-
sification of drugs in pregnancy), a selective alpha-2 agonist, 
acts similarly and is comparable to methyldopa with respect 
to efficacy, but regarding to some safety concern there is 
a small controlled follow-up study with neonates that re-
ported an excess of sleep disturbance in clonidine-exposed 
infants. So, in pregnancy, it is recommended to be used as a 
third-line agent for multidrug control of refractory hyper-
tension [10, 18].
For second-line treatment our doctors recommended 
calcium channel blockers (CCB) – in 36.36% of cases, alpha-
adrenoblockers – in 24.24% of cases, beta-blockers (BB) – in 
21.214% of cases, diuretics – in 12.12% of cases and 3% for 
angiotensin-converting-enzyme inhibitors (ACE inhibi-
tors) and angiotensin receptor blockers (ARB).
Calcium channel blockers have been used to treat chro-
nic hypertension, mild pre-eclampsia presenting late in 
gestation and urgent hypertension associated with pre-ec-
lampsia (Category C, less safe, accordingly to FDA classifi-
cation of drugs in pregnancy, but amlodipine is classified as 
Category D-Teratogenicity in animals). Both nifedipine and 
verapamil are not associated with teratogenic risks to fetus 
exposed in first trimester. Maternal adverse effects with 
nifedipine include pharmacodinamic type as tachycardia, 
palpitations, peripheral edema, headaches, and facial flush-
ing. Nifedipine does not seem to cause a detectable decrease 
in uterine blood flow. Short-acting dihydropyridine cal-
cium antagonists sublingually are associated with maternal 
hypotension and fetal distress and are generally not recom-
mended. In contrast long-acting oral nifedipine in pregnant 
patients with severe hypertension during pregnancy has 
been shown to be safe and effective. Dihydropyridine com-
pounds: I-generation (nifedipine); II generation (felodipine, 
isradipine, nicardipina) also have a tocolytic effect and can 
delay the onset or slow the progression of labor. Phenylal-
kylamine agent as verapamil and benzothiazepine class as 
diltiazem may have additional value in women with pro-
teinuria because of their antiproteinuric action [3, 4, 10, 18].
Both groups alpha-adrenoblockers and beta-blockers 
(BB) are recommended by our doctors with the same fre-
quency (pindolol and acebutolol are classified as Category 
B, but atenolol, propronalol, metoprolol, timolol and la-
betalol – Categoty C). Accordingly to Cochrane analysis, 
beta-blockers were found to be more effective in lowering 
blood pressure than methyldopa. Labetalol, a nonselective 
alpha-and beta-blocker has obtained wide acceptance to 
treat  sever hypertension in pregnancy, because of lower in-
cidence of  side effects in comparison with hydralazine- di-
rect vasodilator Category C, associated with more maternal 
and perinatal adverse events, than other agents when used 
acutely [10,18].
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Diuretics were recommended in 12.12% of cases, hy-
drochlorthiazide (Category B, safe), accordingly to FDA 
classification of drugs in pregnancy). Administration of di-
uretics in pregnancy remains a matter of dispute because 
of fluid and electolytes disturbances. The potassium sparing 
diuretics spironolactone, triamterene and amilorid are not 
recommended in pregnancy – Category D (teratogenicity in 
animals, accordingly to FDA classification of drugs in preg-
nancy).
Angiotensin-converting-enzyme inhibitors (ACE in-
hibitors) and angiotensin receptor blockers (ARB) were 
recommended in 3% of cases. These groups of antihyper-
tensive agents that are used as first-line  choice  in treat-
ment of essential hypertension are contraindicated in preg-
nancy because of severe toxicity secondary to reduced renal 
perfusion of the fetal kidneys (Category D, teratogenicity 
in animals, accordingly to FDA classification of drugs in 
pregnancy). Their use has been associated with renal dys-
genesis, oligohydramnios as consequence of fetal oliguria, 
pulmonary hypoplasia, intrauterine growth restriction, and 
neonatal anuric renal failure, leading to death of the fetus. 
ARBs have also been associated with fetal demise and same 
concerns are applicable to the use of direct renin inhibitors. 
First trimester exposure to these agents has been associated 
with greater incidence of cardiovascular and central ner-
vous system malformations. Whether these effects are sec-
ondary to hemodynamic effects or specific requirement of 
angiotensin II as a fetal growth factor is unknown. Patients 
should, therefore, be counseled to stop these medications 
while attempting to conceive. The risk of birth defects in-
creased from 3 to 7% while on these medications at the time 
of conception [8, 10, 12, 13,18].
For treatment pre-eclampsia and eclampsia seizures in 
84.85% of cases doctors recommended magnesium sulfate 
(Category A, most safe, accordingly to FDA classification of 
drugs in pregnancy).
Conclusions
On the basis of carried out study, it was found that ACE 
inhibitors, diuretics, BAB, CCB and ARB have been first-line 
drugs in the AHT treatment. The drugs selection was per-
formed on the basis of national and international guidelines 
and the pharmacological properties of the antihypertensive 
drug groups. The use of second-line antihypertensive drugs 
(central-acting alpha-2-adrenomimetics, imidazolinone de-
rivatives, alpha-1 adrenoblockers) denotes that the choice 
of antihypertensive therapy also takes into account the par-
ticularities of AHT evolution in the patient, especially in de-
tected associated diseases and metabolic disturbances.
Based on the results obtained from the questionnaire 
on the treatment of pregnancy-induced hypertension, it 
was demonstrated that first-line agents remain central act-
ing agent, alpha 2 adrenoreceptor agonist like methyldopa, 
which is in conformity with national and international pro-
tocols and guidelines. As second-line choice in the treat-
ment of pregnancy-induced hypertension we can mention 
calcium channel blockers (CCB), alpha-adrenoblockers, 
beta-blockers and diuretics. As third-choice in treatment of 
sever hypertension in preeclampsia are selected direct va-
sodilators as hydralazine, labetalol, sodium nitroprusside 
and the most widely used in preeclampsia and eclampsia 
remains magnesium sulfate. It is very important to note that 
angiotensin-converting-enzyme inhibitors (ACE inhibi-
tors) and angiotensin receptor blockers are contraindicated 
in pregnancy and must not be recommended for pregnan-
cy-induced hypertension. 
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